(Reuters) – The U.S. Food and Drug Administration approved AstraZeneca Plc’s combo treatment for a form of lung cancer in previously untreated patients, the drugmaker said on Monday.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Shounak Dasgupta)
